Patients With Selected Advanced Solid Tumors clinical trials

Explore recruiting patients with selected advanced solid tumors clinical trials.

Recruiting patients with selected advanced solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Patients With Selected Advanced Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors

Spain, France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors (NIRADO)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Patients With Selected Advanced Solid Tumors trials by city

Patients With Selected Advanced Solid Tumors in Toronto Patients With Selected Advanced Solid Tumors in Vancouver Patients With Selected Advanced Solid Tumors in Montreal Patients With Selected Advanced Solid Tumors in Calgary Patients With Selected Advanced Solid Tumors in Edmonton Patients With Selected Advanced Solid Tumors in Ottawa Patients With Selected Advanced Solid Tumors in Winnipeg Patients With Selected Advanced Solid Tumors in Quebec City Patients With Selected Advanced Solid Tumors in Hamilton Patients With Selected Advanced Solid Tumors in Kitchener Patients With Selected Advanced Solid Tumors in London Patients With Selected Advanced Solid Tumors in Halifax Patients With Selected Advanced Solid Tumors in New York Patients With Selected Advanced Solid Tumors in Los Angeles Patients With Selected Advanced Solid Tumors in Chicago Patients With Selected Advanced Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease